Prostate cancer and the Will Rogers phenomenon

Journal of the National Cancer Institute

Volumn 97, Issue 17, 2005, Pages 1248-1253

  Albertsen, Peter C ^a   Hanley, James A H ^b   Barrows, George H ^c   Penson, David F ^d   Kowalczyk, Pam D H ^c   Sanders, M Melinda ^a   Fine, Judith ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ARTIFACT; CALCULATION; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER TISSUE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATHOLOGIST; PHENOMENOLOGY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; STANDARDIZATION; STATISTICAL SIGNIFICANCE; UNITED STATES; BIOPSY; BLOOD; CANCER STAGING; CLINICAL TRIAL; EPIDEMIOLOGY; HOSPITALIZATION; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; REGISTER; TREATMENT OUTCOME;

PROSTATE SPECIFIC ANTIGEN;

AGED; BIAS (EPIDEMIOLOGY); BIOPSY; CLINICAL TRIALS; CONNECTICUT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 24744432101     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji248     Document Type: Article

References (20)

1. Albertsen PC, Fryback DG, Storer DE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:69-74.
2. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24.
3. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration. J Clin Oncol 1999;17:3167-72.
4. Han M, Partin AW, Piantadosi S, Epstein JI, Wash PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-9.
5. D'Amico AV, Chen M, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, et al. Changing prostate specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate specific antigen era. Int J Radiat Oncol Biol Phys 2002;54:436-41.
6. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
7. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000;283:2975-8.
8. Gilliland FD, Gleason DF, Hunt WC, Stone N, Harlan LC, Key CR. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. J Urol 2001;165:846-50.
9. Chism DB, Hanlon AL, Tronsco P, Al-Saleem T, Horowitz EM, Pollack A. The Gleason score shift: Score four and seven years ago. Int J Radiat Oncol Biol Phys 2003;56:1241-7.
10. Smith EB, Frierson HF Jr, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years. Cancer 2002;94:2282-7.
11. Schellhammer P, Moriarty R, Bostwick D, Kuban D. Fifteen-year minimum follow-up of a prostate brachytherapy series: Comparing the past with the present. Urology 2000;56:436-9.
12. Kondylis FI, Moriarty RP, Bostwick D, Schellhammer P. Prostate cancer grade assignment: The effect of chronological, interpretive and translation bias. J Urol 2003;170:1189-93.
13. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol 2000;24:477-8.
14. Charlson ME, Pompei P, Alex KL, MacKenzi CR. A new method of classifying prognostic co-morbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
15. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
17. Hutchinson GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst 1968;41:665-73.
18. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. New Engl J Med 1985;312:1604-8.
19. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, et al. Changes in the 2003 American joint committee cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003;21:3244-8.
20. Pan C, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens. Am J Surg Pathol 2000;24:563-9.